novo nordisk semaglutide patent Off-patent in 2026: the next revolution in anti-obesity medications Novo Nordisk Settles Ozempic Patent

Semaglutide (Ozempic and Wegovy) is a glucagon-like peptide-1 (GLP-1) receptor agonist

For those who experience severe or persistent skin reactions, considering alternative medications might be an option

Your provider may recommend: Shorter time at the 2.5 mg initiation dose (3 weeks instead of 4) More aggressive titration to reach therapeutic levels sooner Targeting higher maintenance doses (12.5 to 15 mg) from the outset Closer monitoring of side effects to balance speed with tolerance The microdosing alternative for sensitive switchers Not everyone needs or wants to follow the standard titration

However, a sudden decrease in fat mass can impact estrogen production, leading to temporary menstrual irregularities